Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EMBC 
Embecta Corp (EMBC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: EMBC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.95% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 853.30M USD | Price to earnings Ratio 10.21 | 1Y Target Price 16.67 |
Price to earnings Ratio 10.21 | 1Y Target Price 16.67 | ||
Volume (30-day avg) 5 | Beta 1.04 | 52 Weeks Range 9.10 - 20.58 | Updated Date 08/29/2025 |
52 Weeks Range 9.10 - 20.58 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 4.11% | Basic EPS (TTM) 1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate 0.77 | Actual 1.12 |
Profitability
Profit Margin 7.58% | Operating Margin (TTM) 35.43% |
Management Effectiveness
Return on Assets (TTM) 3.8% | Return on Equity (TTM) - |
Valuation
Trailing PE 10.21 | Forward PE - | Enterprise Value 2118234225 | Price to Sales(TTM) 0.77 |
Enterprise Value 2118234225 | Price to Sales(TTM) 0.77 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 9.38 | Shares Outstanding 58485100 | Shares Floating 57239386 |
Shares Outstanding 58485100 | Shares Floating 57239386 | ||
Percent Insiders 0.47 | Percent Institutions 101.71 |
Upturn AI SWOT
Embecta Corp
Company Overview
History and Background
Embecta Corp. was spun off from Becton, Dickinson and Company (BD) on April 1, 2022. It focuses solely on diabetes care, leveraging BD's established insulin delivery device business. The company's roots are in BD's long history of developing and manufacturing diabetes-related products.
Core Business Areas
- Insulin Delivery: Embecta Corp focuses on insulin pen needles and syringes for diabetes management. These products are essential for patients who require insulin injections.
Leadership and Structure
Devdatt (Dev) Kurdikar is the CEO. The organizational structure is designed to support global sales and manufacturing of insulin delivery devices.
Top Products and Market Share
Key Offerings
- Insulin Pen Needles: Embecta produces and sells a variety of insulin pen needles of different gauges and lengths. Competitors include Novo Nordisk (NovoFine), Medtronic, and Owen Mumford. No specific market share data available in public sources. However, Embecta is a major player in this segment due to BD's legacy.
- Insulin Syringes: Embecta manufactures and distributes insulin syringes, predominantly for markets outside the United States. Competitors include B. Braun and Terumo. Market share data not publicly available.
Market Dynamics
Industry Overview
The diabetes care market is experiencing growth due to the rising prevalence of diabetes globally. The market is competitive, with various companies offering different types of insulin delivery solutions.
Positioning
Embecta Corp. is positioned as a leading global player in insulin delivery devices, specifically pen needles and syringes, leveraging established manufacturing capabilities and distribution networks acquired from BD.
Total Addressable Market (TAM)
The global diabetes care devices market is estimated at over $25 billion. Embecta is positioned to capture a share of this TAM by focusing on insulin delivery devices.
Upturn SWOT Analysis
Strengths
- Established brand reputation from BD
- Global distribution network
- Focus on essential diabetes care products
- Strong manufacturing capabilities
Weaknesses
- Limited product diversification (primarily insulin delivery)
- Reliance on pricing and reimbursement pressures
- Spun-off company; dependent on previous parent company
- Smaller size compared to competitors
Opportunities
- Expanding into new geographic markets
- Developing innovative insulin delivery solutions
- Acquiring complementary businesses
- Partnering with diabetes technology companies
Threats
- Increasing competition from established players
- Technological advancements in alternative insulin delivery methods (e.g., insulin pumps)
- Regulatory changes impacting diabetes care
- Pricing pressures from healthcare providers and payers
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Medtronic (MDT)
- B. Braun Melsungen AG (No US Stock)
- Terumo Corporation (No US Stock)
Competitive Landscape
Embecta's advantage lies in its focused approach to insulin delivery devices, while competitors like Novo Nordisk and Medtronic have broader diabetes care portfolios. Embecta needs to innovate and compete effectively on price and product features.
Growth Trajectory and Initiatives
Historical Growth: Embecta's historical growth is tied to the legacy BD diabetes care business.
Future Projections: Future growth depends on Embecta's ability to innovate, expand geographically, and capitalize on the increasing prevalence of diabetes.
Recent Initiatives: Embecta is focused on operational excellence, supply chain optimization, and growing market share in existing product categories. The company is actively investing into R&D to improve and create new products.
Summary
Embecta Corp is a focused diabetes care company specializing in insulin delivery devices. Its spin-off from BD provides it a dedicated operational structure. While it faces stiff competition, Embecta's established brand and global reach provide a solid foundation. The company's future hinges on its ability to innovate and capture a greater share of the diabetes care market amidst ongoing technological shifts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Analyst reports
- Industry publications
- Company 10K Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on available estimates and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 2100 | Website https://www.embecta.com |
Full time employees 2100 | Website https://www.embecta.com | ||
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.